17 18 71 39 175 46 51 216 110 464 22 126 185 PHASE 0 PHASE I PHASE I/II PHASE II PHASE II/III PHASE III PHASE IV PHASE III PHASE II PHASE I PRECLINICAL DISCOVERY MARKETED LOOK Clinical Assets in 2018 Clinical Trials By Status Source: Drugs by Phase 5 = PMA 219 = 510(K) ALL APPROVALS 54 39 20 15 15 11 Drugs and Trials by Therapy Area DRUGS TRIALS TOTAL DRUGS & TRIALS FOR THERAPY AREA # CARDIOVASCULAR L NERVOUS SYSTEM DERMATOLOGY THROAT DISORDERS GASTROINTESTINAL ENETIC DISORDERS YSTEM & SEX HORMONES OGICAL DISORDERS MONAL DISORDERS IMMUNOLOGY NFECTIOUS DISEASE MALE HEALTH TABOLIC DISORDERS DENTAL DISORDERS ELETAL DISORDERS IGNANT DISORDERS ITIONAL DISORDERS ONCOLOGY OPHTHALMOLOGY OTHER DISEASES RESPIRATORY TOXICOLOGY UNDISCLOSED WOMEN'S HEALTH 190 244 71 8 39 36 31 33 16 111 199 18 172 6 55 604 45 21 94 8 30 18 3 8 0 300 200 100 DIAGNOSTIC IMAGING 5 // 3 NEPHROLOGY & UROLOGY 1 // 15 ENT DEVICES 1 // 19 IN VITRO DIAGNOSTICS 53 // 1 NEUROLOGY DEVICES 4 // 11 HOSPITAL SUPPLIES 0 // 11 SPECIALIZED SECTORS 8 // 31 DENTAL DEVICES 2 // 16 2019 - 2020 3 2019-2020 / / BIOSCIENCECOLORADO